Colorado-based device maker Zynex (OTC:ZYXI) won FDA clearance for its InWave device, an electrotherapy system for treating female urinary incontinence.
The company’s hoping that the InWave device will complement its existing electrotherapy portfolio and spur a boost in revenue, CEO Thomas Sandgaard said in a press release.
Zynex, founded in 1996, operates under 3 business divisions that deal separate with electrotherapy, stroke and spinal cord repair, and cardiac monitoring.
The Zynex Medical division develops electrotherapy systems for pain management and rehabilitation.
Zynex’s NeuroDiagnostics arm deals in stroke and spinal cord injury treatments, and is currently expanding, through strategic acquisitions and product development, into markets for EMG, EEG, sleep pattern, auditory and nerve conductivity neurological diagnosis, according to the company.
Zynex Monitoring Solutions, a development-stage unit, was established to explore the market for non-invasive cardiac monitoring.